The use of recombinant activated factor VII in patients with acquired haemophilia

Acquired haemophilia (AH) is a rare, often severe bleeding disorder characterised by autoantibodies to coagulation factor VIII (FVIII). Observational studies offer crucial insight into the disease and its treatment. Recombinant activated factor VII (rFVIIa, eptacog alfa activated) was available on an emergency and compassionate use basis from 1988 to 1999 at sites in Europe and North America. In 1996, rFVIIa was approved in Europe for the treatment of AH; it was licensed for this indication in the United States in 2006.

Source: Blood Reviews - June 1, 2015 Category: Hematology Authors: Andreas Tiede, Kagehiro Amano, Alice Ma, Per Arkhammar, Soraya Benchikh el Fegoun, Anders Rosholm, Stephanie Seremetis, Francesco Baudo Source Type: research